Metastatic Urothelial Cancer clinical trials

Explore recruiting metastatic urothelial cancer clinical trials.

Recruiting metastatic urothelial cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Urothelial Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

C5701002/SGN22E-002 - A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Portugal, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

IZABRIGHT-BLADDER01: A Randomized, Open-label, Phase 2/3 trial of Izalontamab Brengitecan versus platinum-based chemotherapy for metastatic urothelial cancer in participants with disease progression on or after an immunotherapy-based treatment

Ireland, Belgium, Germany, Italy, Norway, Spain +5 more

Phase II and Phase III (Integrated) EU CTIS Study details

Phase II non randomized clinical trial of NIVOLUMAB/IPILIMUMAB maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer (SOGUG-VEXILLUM)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

PembrolizuMab beyond RECIST progression and oral metroNOmic cyclophosphamide in meTAstatic UROthelial cancer: a single-arm, monocentre, phase 2 trial: minotaURO study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Spain

Phase II and Phase III (Integrated) EU CTIS Study details

Metastatic Urothelial Cancer trials by city

Metastatic Urothelial Cancer in Toronto Metastatic Urothelial Cancer in Vancouver Metastatic Urothelial Cancer in Montreal Metastatic Urothelial Cancer in Calgary Metastatic Urothelial Cancer in Edmonton Metastatic Urothelial Cancer in Ottawa Metastatic Urothelial Cancer in Winnipeg Metastatic Urothelial Cancer in Quebec City Metastatic Urothelial Cancer in Hamilton Metastatic Urothelial Cancer in Kitchener Metastatic Urothelial Cancer in London Metastatic Urothelial Cancer in Halifax Metastatic Urothelial Cancer in New York Metastatic Urothelial Cancer in Los Angeles Metastatic Urothelial Cancer in Chicago Metastatic Urothelial Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease